Identifying Microglia and Peripheral Infiltrating Macrophages in the Injured Spinal Cords Using Flow Cytometry

Yu-Qing Chen1, Jian-Xiong Gao2, Hua-Zheng Yan2

  • 1Clinical Laboratory, the First Affiliated Hospital of Bengbu Medical University; Department of Biochemistry and Molecular Biology, School of Laboratory Medicine, Bengbu Medical University.

Insights

After spinal cord injury (SCI), distinguishing between microglia (MG) and macrophages (Mø) is challenging. This study presents a flow cytometry method to identify M1/M2-like MG and Mø phenotypes based on specific marker expression.

Area of Science:

  • Neuroscience
  • Immunology
  • Cell Biology

Background:

  • Microglia (MG) and peripheral macrophages (Mø) are key immune cells in the spinal cord.
  • Following spinal cord injury (SCI), MG activation and Mø infiltration are critical pathological processes.
  • Differentiating pro-inflammatory (M1-like) and anti-inflammatory (M2-like) phenotypes of MG and Mø is difficult due to overlapping markers.

Purpose of the Study:

  • To develop a reliable flow cytometry (FCM) protocol for distinguishing M1/M2-like microglia and macrophages after SCI.
  • To establish a method for analyzing the distinct roles of these immune cell phenotypes in SCI pathogenesis.

Main Methods:

  • Utilized flow cytometry (FCM) to analyze cell surface and intracellular markers.
  • Optimized FCM for stable detection of microglia and macrophages in the injured spinal cord.
  • Identified specific cell populations using CD45, CD11b, CD68, and CCR7 marker expression profiles.

Main Results:

  • Developed a protocol to differentiate M1/M2-like MG and Mø phenotypes.
  • CD11b+CD45-/lowCD68+CCR7+ cells identified as M1-like MG.
  • CD11b+CD45-/lowCD68+CCR7- cells identified as M2-like MG.
  • CD11b+CD45highCD68+CCR7+ cells identified as M1-like Mø.
  • CD11b+CD45highCD68+CCR7- cells identified as M2-like Mø.

Conclusions:

  • The established FCM method enables precise identification of M1/M2-like microglia and macrophages post-SCI.
  • This protocol aids in understanding the specific contributions of different immune cell phenotypes to spinal cord injury.
  • Facilitates further research into targeted immunomodulatory therapies for SCI.

Related Concept Videos